COVID-19 Clinical Trial
Official title:
Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial
In-vitro studies revealed that nafamostat mesylate has antiviral activity against Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-inflammatory and
anti-coagulation effect. However, there is no clinical studies on the efficacy of nafamostat
in patients with COVID-19.
This study is conducted to evaluate the clinical efficacy of nafamostate mesylate in adult
patients hospitalized with COVID-19 pneumonia.
- The COVID-19 epidemic expanded to the whole world since it started from the Wuhan area
in China in Dec. 2019. The Republic of Korea experiences a sharp increase in the patient
since 24th Feb. 2020. An analysis of more than 70,000 patients in China, about 15% of
them cause severe pneumonia, 5% require treatment in the intensive care unit, half of
them die of the disease.
- There is no proven therapeutics for COVID-19 patients yet. Currently, the treatment with
Kaletra, Hydroxychloroquine, etc. did not show apparent effect, and there are no other
drugs that can apply to patients who get worse even with those drugs or severe.
- There are research reports that defective innate immunity and accelerated activation of
the complement cascade, caused by the SARS-CoV-2, induce rapidly progressing
pneumonitis.
- Action mechanism of Nafamostat mesilate A. Show anti-viral effect by an inhibition
serine protease, which is required for the host membrane fusion of viral envelop
protein. In vitro experiments showed that the drug is effective in MERS-CoV,
Influenza virus, and SARS-CoV-2.
B. Show anti-inflammatory effect by inhibition of the complement pathway, and inhibition of
cytokine production.
This study is conducted to evaluate the clinical efficacy of nafamostate mesylate in adult
patients hospitalized with COVID-19 pneumonia.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|